A review: Mechanism of action of antiviral drugs
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Antiviral drugs are a class of medicines particularly used for the treatment of viral infections. Drugs that combat viral infections are called antiviral drugs. Viruses are among the major pathogenic agents that cause number of serious diseases in humans, animals and plants. Viruses cause many diseases in humans, from self resolving diseases to acute fatal diseases. Developing strategies for the antiviral drugs are focused on two different approaches: Targeting the viruses themselves or the host cell factors. Antiviral drugs that directly target the viruses include the inhibitors of virus attachment, inhibitors of virus entry, uncoating inhibitors, polymerase inhibitors, protease inhibitors, inhibitors of nucleoside and nucleotide reverse transcriptase and the inhibitors of integrase. The inhibitors of protease (ritonavir, atazanavir and darunavir), viral DNA polymerase (acyclovir, tenofovir, valganciclovir and valacyclovir) and of integrase (raltegravir) are listed among the Top 200 Drugs by sales during 2010s. Still no effective antiviral drugs are available for many viral infections. Though, there are a couple of drugs for herpesviruses, many for influenza and some new antiviral drugs for treating hepatitis C infection and HIV. Action mechanism of antiviral drugs consists of its transformation to triphosphate following the viral DNA synthesis inhibition. An analysis of the action mechanism of known antiviral drugs concluded that they can increase the cell’s resistance to a virus (interferons), suppress the virus adsorption in the cell or its diffusion into the cell and its deproteinisation process in the cell (amantadine) along with antimetabolites that causes the inhibition of nucleic acids synthesis. This review will address currently used antiviral drugs, mechanism of action and antiviral agents reported against COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, K.-T., Wong, A. Y.-L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P.-H., Huang, X., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104786 · Cited by 922
Fyfe, J. A., Keller, P. M., Furman, P. A., Miller, R. L., & Elion, G. B. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34236-9 · Cited by 562
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
Dolin, R., Reichman, R. C., Madore, H. P., Maynard, R., Linton, P. N., & Webber-Jones, J. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209023071002 · Cited by 501
Tyring, S., Barbarash, R. A., Nahlik, J. E., Cunningham, A., Marley, J., Heng, M., Jones, T., Rea, T., Boon, R., Saltzman, R., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-2-199507150-00002 · Cited by 491
Fusing structure and function: a structural view of the herpesvirus entry machinery
Connolly, S. A., Jackson, J. O., Jardetzky, T. S., & Longnecker, R. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2548 · Cited by 477
Huggins, J. W., Hsiang, C. M., Cosgriff, T. M., Guang, M. Y., Smith, J. I., Wu, Z. O., LeDuc, J. W., Zheng, Z. M., Meegan, J. M., Wang, Q. N., et al. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/164.6.1119 · Cited by 463
Pharmacokinetics of acyclovir after intravenous and oral administration
de Miranda, P., & Blum, M. R. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/12.suppl_b.29 · Cited by 381
Safrin, S., Crumpacker, C., Chatis, P., Davis, R., Hafner, R., Rush, J., Kessler, H. A., Landry, B., & Mills, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108223250805 · Cited by 375
Antiviral treatment of COVID-19
ŞİMŞEK YAVUZ, S., & ÜNAL, S. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-145 · Cited by 367
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
McCreary, E. K., & Pogue, J. M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa105 · Cited by 334
Soul-Lawton, J., Seaber, E., On, N., Wootton, R., Rolan, P., & Posner, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2759 · Cited by 315
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Rossignol, J.-F. (2016) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.04.001 · Cited by 290
Induction of Both Thymidine and Deoxycytidine Kinase Activity by Herpes Viruses
Jamieson, A. T., Gentry, G. A., & Subak-Sharpe, J. H. (1974) · Journal of General Virology · doi:10.1099/0022-1317-24-3-465 · Cited by 288
Meyers, J. D., Wade, J. C., Mitchell, C. D., Saral, R., Lietman, P. S., Durack, D. T., Levin, M. J., Segreti, A. C., & Balfour, H. H. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90097-3 · Cited by 261
The broad spectrum antiviral agent ribavirin inhibits capping of mRNA
Goswami, B. B., Borek, E., Sharma, O. K., Fujitaki, J., & Smith, R. A. (1979) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(79)91853-9 · Cited by 208
Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase.
Furman, P. A., St Clair, M. H., & Spector, T. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42739-6 · Cited by 197
Antivirals for COVID-19: A critical review
Frediansyah, A., Tiwari, R., Sharun, K., Dhama, K., & Harapan, H. (2021) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2020.07.006 · Cited by 185
Q&A: What are pathogens, and what have they done to and for us?
Balloux, F., & van Dorp, L. (2017) · BMC Biology · doi:10.1186/s12915-017-0433-z · Cited by 182
Derse, D., Cheng, Y. C., Furman, P. A., St Clair, M. H., & Elion, G. B. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68420-6 · Cited by 180
Antimicrobial Agents and Chemotherapy
Perlman, D. (1968) · Science · doi:10.1126/science.160.3827.562 · Cited by 139
The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
Jasenosky, L. D., Cadena, C., Mire, C. E., Borisevich, V., Haridas, V., Ranjbar, S., Nambu, A., Bavari, S., Soloveva, V., Sadukhan, S., et al. (2019) · iScience · doi:10.1016/j.isci.2019.07.003 · Cited by 138
Lodish, H. F., & Rose, J. K. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40638-7 · Cited by 121
Benzothiazoles as potential antiviral agents
Asiri, Y. I., Alsayari, A., Muhsinah, A. B., Mabkhot, Y. N., & Hassan, M. Z. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13331 · Cited by 110
How to Discover Antiviral Drugs Quickly
Parks, J. M., & Smith, J. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmcibr2007042 · Cited by 101
Cheng, Y., Domin, B. A., Sharma, R. A., & BOBEK, M. (1976) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.10.1.119 · Cited by 100
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
Jomah, S., Asdaq, S. M. B., & Al‐Yamani, M. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.07.013 · Cited by 94
Shin, W.-J., & Seong, B. L. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1560261 · Cited by 54
Cited by
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Synergistic Effects Between Metal Nanoparticles and Commercial Antimicrobial Agents: A Review
Ribeiro, A. I., Dias, A. M., & Zille, A. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c03891 · Cited by 276
Ferro-catalysis Bioelectronics: Progress and Prospects
Tang, X., Liu, Y., Li, L., Song, Y., Dai, Y., Yang, Y., Yuan, G., & Wang, Y. (2024) · Nano Energy · doi:10.1016/j.nanoen.2023.109059 · Cited by 8
Metadata
- Authors
- Kausar, S., Said Khan, F., Ishaq Mujeeb Ur Rehman, M., Akram, M., Riaz, M., Rasool, G., Hamid Khan, A., Saleem, I., Shamim, S., & Malik, A.
- Venue
- International Journal of Immunopathology and Pharmacology
- Publisher
- SAGE Publications
- Published
- 2021-03
- Volume
- 35
- Pages
- 20587384211002621-20587384211002621
- ISSN
- 0394-6320 (ISSN-L)
- 2058-7384
- OpenAlex
- W3136190261
- Cited by
- 429
- References
- 30
- FWCI
- 19.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.